- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
- The Hot Pink Party
You are here
PRESS RELEASE: The Breast Cancer Research Foundation Announces the Continued Expansion of the Drug Research Collaborative to Speed the Delivery of New Treatment Options
NEW YORK, NY – December 11, 2019 – The Breast Cancer Research Foundation (BCRF) announced $5 million in funding provided by Eli Lilly and Company to conduct investigator-initiated studies of the CDK4 & 6 inhibitor, Verzenio® (abemaciclib).
Raise money for lifesaving research this holiday season and throughout the new year.
BCRF attended the fifth annual Conquer Cancer Scientific and Career Development Retreat designed to empower early career researchers.
Learn how you can become a Team BCRF runner in this year’s 13.1-mile race
The inspiration of a BCRF metastasis researcher, recaps from signature events, ASCO 2019 science updates and more
A BCRF researcher since 2003, Dr. Winer will be recognized for his pioneering achievements made in breast cancer research.
BCRF is the largest private funder of metastatic breast cancer research in the world.
Mapping and understanding brain metastasis
The network’s campaign features a new PSA and content centered around their commitment to BCRF.
BCRF announces research priorities for 2019-2020, including $27 million for MBC research.